Trial Profile

Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir (Primary) ; Atazanavir/ritonavir
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms SUAT

Most Recent Events

09 Jan 2017 Primary endpoint (Proportion of subjects without treatment failure at 48 weeks) has not been met, according to results published in the HIV Clinical Trials Journal.
09 Jan 2017 Results published in the HIV Clinical Trials Journal.
16 Jun 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com